Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 16Fallopian Tube Neoplasms 7Carcinoma, Ovarian Epithelial 6Ovarian Cancer Recurrent 2Multiple Myeloma 2Melanoma 2Colorectal Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-resistant Recurrent Ovarian Cancer 1Platinum-resistant Ovarian Cancer 1Peritoneal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Lymphoma, Follicular 1Lymphoma 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Malignancies 1Adenoviridae Infections 1

Interventions

Carboplatin 13Paclitaxel 8Bevacizumab 7Gemcitabine 4130-nm albumin-bound paclitaxel 4liposomal doxorubicin 3relacorilant 2pembrolizumab 2nintedanib 2epothilone B 2Drug Therapy 2Albumin-Bound Paclitaxel 2volociximab 1tremelimumab 1phenoxodiol 1oregovomab 1olaparib 1lanreotide 1farletuzumab 1enzastaurin 1durvalumab 1cc-486 1catumaxomab 1atezolizumab 1Trastuzumab 1Trabectedin 1Topotecan 1Saline Solution 1Oxaliplatin 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peritoneal Neoplasms × 1-dodecylpyridoxal × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡